13F Holdings
中文EN

RAPP Rapport Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2012593 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-54.0%
TTM EPS YoY-39.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.3%
ROA-31.5%
ROIC (approx.)-45.9%
Asset turnover—

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio20.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$94.79M$60.94M$28.00M
SG&A expense$30.31M$22.12M$8.18M
Operating income-$125.10M-$83.06M-$36.18M
Pretax income—-$78.31M-$34.78M
Income tax$0$0$10,000
Net income-$111.48M-$78.31M-$34.79M
EBITDA-$124.08M-$82.22M-$36.07M
EPS (basic)-2.86-3.78-23.10
EPS (diluted)-2.86-3.78-23.10
Weighted avg. shares (diluted)38.93M20.74M1.51M
Balance sheet
Cash & equivalents$52.65M$56.80M$70.17M
Short-term investments$437.89M$248.47M$77.31M
Receivables$0——
Current assets$498.56M$309.80M$150.87M
PP&E, net$2.98M$3.53M$1.92M
Total assets$512.43M$314.93M$155.42M
Current liabilities$19.05M$8.77M$8.80M
Total liabilities$27.78M$9.51M$14.48M
Shareholders' equity$484.65M$305.43M-$25.63M
Shares outstanding47.77M36.58M4.17M
Cash flow statement
Operating cash flow-$87.47M-$64.83M-$27.18M
Capital expenditure$616,000$2.40M$1.64M
Free cash flow-$88.09M-$67.23M-$28.82M
Investing cash flow-$187.47M-$170.14M-$78.86M
Financing cash flow$270.79M$221.62M$145.14M
Depreciation & amortization$1.02M$839,000$112,000
Stock-based compensation$18.86M$10.23M$3.52M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.